Prostate Cancer Trial, Recruiting NCT06163924 Sponsor: Chinese University of Hong Kong Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06163924
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men between 18 and 80 years old
  • People who have been diagnosed with prostate cancer, either confirmed through a tissue sample (biopsy) or through clinical assessment by a doctor
  • People who are planned to receive hormone-blocking treatment (called ADT) for at least one year

Who may not be able to join:

  • People who have a history of serious heart or artery disease, including: a major heart attack or chest emergency in the past 12 months, a previous heart attack, a previous stroke caused by a blocked blood vessel, or significant leg artery disease causing pain when walking (confirm with trial site for full details on how this is assessed)
  • People who have received hormone therapy as part of prostate cancer treatment within the past year before joining
  • People who are unable or unwilling to sign a written consent form
  • People who are currently taking part in another research study that involves treatments outside of normal clinical care

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 852-3505-3933

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
10 December 2023
Est. completion
31 December 2028

Where this trial is recruiting

Hong Kong

Primary endpoints

The change in Framingham Risk Score between baseline and 1-year after ADT.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov